Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient.
暂无分享,去创建一个
N. Agrawal | F. Cardarelli | Neil Roy | Danwen Yang | Katelyn R. Richards | M. Nahas | Chelsea Marcus
[1] Yangqiu Li,et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma , 2017, Oncotarget.
[2] H. Goldschmidt,et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[3] A. Palumbo,et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[4] G. Guron,et al. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide , 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[5] A. Hertig,et al. Minimal change disease and lenalidomide. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] A. Israni,et al. Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.
[7] D. Seldin,et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] K. Jhaveri,et al. Reversible Fanconi syndrome due to lenalidomide , 2008, NDT plus.
[9] G. Morgan,et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.